The Competition Commission of India (CCI) is studying whether Google and Microsoft’s bundling of AI tools with office suites violates…
NFRA-2 is an annual return that statutory auditors of listed and specified classes of unlisted companies must file with the…
CII is finalizing a national framework for Global Capability Centers (GCCs) to boost growth in tier-II and III cities. The…
The central drugs regulator has ordered manufacturers and importers of Class C and D medical devices to update their inventories…
The cabinet has cleared a Rs 4,447 crore greenfield highway corridor in Bihar and a Rs 3,169 crore rail line…
Govt extends fast-track merger route to more firms, easing M&A approvals and boosting reverse flipping of startups shifting domicile to…
Look-back period for ‘avoidance transactions’ to be indefinite
The government’s IBC Amendment Bill 2025 introduces Section 164A, empowering resolution professionals to reverse fund transfers made before personal insolvency.…
In a significant move, the government has reduced GST on all pharmaceutical formulations from 12% to 5% and exempted 33…
The National Institutional Ranking Framework (NIRF) 2025 results have been announced, with IIT Madras, IISc, and IIT Bombay securing the…
GST Council may cut rates on 36 critical drugs and 25 medical devices, with cancer and rare disease therapies set…
Ahead of the GST Council’s crucial meeting here on September 3-4 to restructure the indirect tax, experts and industry executives…
IBC amendments expand resolution professionals’ powers, making past employees and service providers accountable to share information during insolvency. The move…
Govt may bring artificial intelligence under the upcoming Digital Competition Bill. The move would extend ex-ante antitrust rules to AI,…
AiMeD cautioned that the proposed GST change – to 5% or 18% – present significant risks that require carefully-nuanced consideration.
India’s $3 bn contract research, development and manufacturing (CRDMO) sector is set to grow at 18% CAGR till FY30, says…
The $16-billion ad industry has since come under intense regulatory scrutiny. Srinivasan K. Swamy, the newly-elected president of AAAI, spoke…
A parliamentary committee has criticized the National Pharmaceutical Pricing Authority (NPPA) for allowing a steep 50% price increase on eleven…
